234 related articles for article (PubMed ID: 19932542)
1. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
Joy MS; Gipson DS; Powell L; MacHardy J; Jennette JC; Vento S; Pan C; Savin V; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Am J Kidney Dis; 2010 Jan; 55(1):50-60. PubMed ID: 19932542
[TBL] [Abstract][Full Text] [Related]
2. Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.
Peyser A; Machardy N; Tarapore F; Machardy J; Powell L; Gipson DS; Savin V; Pan C; Kump T; Vento S; Trachtman H
BMC Nephrol; 2010 Jan; 11():2. PubMed ID: 20113498
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.
Joy MS; Gipson DS; Dike M; Powell L; Thompson A; Vento S; Eddy A; Fogo AB; Kopp JB; Cattran D; Trachtman H
Clin J Am Soc Nephrol; 2009 Jan; 4(1):39-47. PubMed ID: 19073787
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
Trachtman H; Vento S; Herreshoff E; Radeva M; Gassman J; Stein DT; Savin VJ; Sharma M; Reiser J; Wei C; Somers M; Srivastava T; Gipson DS
BMC Nephrol; 2015 Jul; 16():111. PubMed ID: 26198842
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Trachtman H; Vento S; Gipson D; Wickman L; Gassman J; Joy M; Savin V; Somers M; Pinsk M; Greene T
BMC Nephrol; 2011 Feb; 12():8. PubMed ID: 21310077
[TBL] [Abstract][Full Text] [Related]
6. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis.
Trachtman H; Fervenza FC; Gipson DS; Heering P; Jayne DR; Peters H; Rota S; Remuzzi G; Rump LC; Sellin LK; Heaton JP; Streisand JB; Hard ML; Ledbetter SR; Vincenti F
Kidney Int; 2011 Jun; 79(11):1236-43. PubMed ID: 21368745
[TBL] [Abstract][Full Text] [Related]
7. Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease.
Roberts BV; Susano I; Gipson DS; Trachtman H; Joy MS
J Clin Pharmacol; 2013 Sep; 53(9):919-24. PubMed ID: 23813330
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
9. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Spino C; Kaskel FJ; Friedman A; Moxey-Mims MM; Fine RN; Gassman JJ; Kopp JB; Walsh L; Wang R; Gipson DS
Am J Kidney Dis; 2021 Feb; 77(2):216-225. PubMed ID: 32791086
[TBL] [Abstract][Full Text] [Related]
10. An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.
Troost JP; Trachtman H; Nachman PH; Kretzler M; Spino C; Komers R; Tuller S; Perumal K; Massengill SF; Kamil ES; Oh G; Selewski DT; Gipson P; Gipson DS
Clin J Am Soc Nephrol; 2018 Mar; 13(3):414-421. PubMed ID: 29167190
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
Li X; Li H; Ye H; Li Q; He X; Zhang X; Chen Y; Han F; He Q; Wang H; Chen J
Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
[TBL] [Abstract][Full Text] [Related]
12. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis.
Chiou YY; Lee YC; Chen MJ
Curr Med Res Opin; 2017 Aug; 33(8):1389-1399. PubMed ID: 28436233
[TBL] [Abstract][Full Text] [Related]
13. Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases.
He HG; Wu CQ; Ye K; Zeng C; Huang YY; Luo SW; Yin W; Ye QR; Peng XM
BMC Nephrol; 2019 Aug; 20(1):328. PubMed ID: 31438882
[TBL] [Abstract][Full Text] [Related]
14. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.
Kachurina N; Chung CF; Benderoff E; Babayeva S; Bitzan M; Goodyer P; Kitzler T; Matar D; Cybulsky AV; Alachkar N; Torban E
Am J Physiol Renal Physiol; 2016 May; 310(10):F1148-56. PubMed ID: 26719363
[TBL] [Abstract][Full Text] [Related]
15. Urine neutrophil gelatinase-associated lipocalin and kidney injury in children with focal segmental glomerulosclerosis.
Youssef DM; El-Shal AA
Iran J Kidney Dis; 2012 Sep; 6(5):355-60. PubMed ID: 22976261
[TBL] [Abstract][Full Text] [Related]
16. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN; Alpers CE; Barratt J; Bieler S; Canetta P; Chae DW; Coppock G; Diva U; Gesualdo L; Heerspink HJL; Inrig JK; Kirsztajn GM; Kohan D; Komers R; Kooienga LA; Lieberman K; Mercer A; Noronha IL; Perkovic V; Radhakrishnan J; Rote W; Rovin B; Tesar V; Trimarchi H; Tumlin J; Wong MG; Trachtman H;
N Engl J Med; 2023 Dec; 389(26):2436-2445. PubMed ID: 37921461
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.
Gipson DS; Trachtman H; Kaskel FJ; Radeva MK; Gassman J; Greene TH; Moxey-Mims MM; Hogg RJ; Watkins SL; Fine RN; Middleton JP; Vehaskari VM; Hogan SL; Vento S; Flynn PA; Powell LM; McMahan JL; Siegel N; Friedman AL
Kidney Int; 2011 Mar; 79(6):678-685. PubMed ID: 21178977
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.
Han KH; Kim SH
Biomed Res Int; 2016; 2016():3053706. PubMed ID: 27195285
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
Rajasekeran H; Reich HN; Hladunewich MA; Cattran D; Lovshin JA; Lytvyn Y; Bjornstad P; Lai V; Tse J; Cham L; Majumder S; Bowskill BB; Kabir MG; Advani SL; Gibson IW; Sood MM; Advani A; Cherney DZI
Am J Physiol Renal Physiol; 2018 Mar; 314(3):F412-F422. PubMed ID: 29141939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
